Share this video  

ELCC 2019 | Afatinib for advanced EGFRm-positive NSCLC

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, presents interim data from a phase IIIB trial, comparing the outcomes of afatinib in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients with or without prior chemotherapy treatment. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter